Forest announced that beginning mid-June 2011, Daliresp (roflumilast tablets) will be available as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

Daliresp, a selective phosphodiesterase-4 inhibitor, will be available in a 500mcg dosage strength tablet.

For more information call (800) 678-1605 or visit www.daliresp.com.